would areas have on in that I to as XXXX: we like four key development, validation, funding. an expansion Brett. performance update well on and are Thanks, focused as progress the market the clinical provide capital we portfolio made recent on
with system installations. Beginning new
Digital January and in have Programs: one three one As in February, one Laparoscopy Senhance we in previously in and hospitals U.S, Europe, Asia. the initiated announced
sites completing it happy case. the to get were between On We and which first days signing XX we an running. able very are speed the up to agreement with these at was average
we area; hospital major university signed Austria. in Feldkirch, multi-specialty hospitals: of Marianna In Hospital, School in a agreements hospital St. have two LKH Medicine Toyoko teaching and the a metropolitan Tokyo addition, other with University Greater
when access to limited While are installing Senhance the of in the timing and is system, training to occur will not restrictions current these that committed two surgeon environment. accounts travel the the given certain
of Shifting pipeline to our strong pipeline, despite we continue environment. to potential hospital have current COVID-XX the a global customers
U.S., once training hospital could the currently can late restrictions relative near and stage Asia that placements recommence, resume. surgeries in term are result multiple discussions Europe in loosened, with are elective and surgeon We the hospitals in in
strategic our largely to leasing system opposed installing Along part will sales. shift We meet we continue hospitals laparoscopic XXXX, these XXXX. lines, late around at to through placements volumes in focus our capital XX with as globe, of to the expect we of in high on systems as that opted goal
We shift this the installations success to increased to expect has us year have later will year agreements and believe operating hospitals when model seen continue positioned using procedures. to that We utilize early hospitals conserve well this to drive elective capital. this reopen lease in
procedure momentum volumes strong volumes. with year-over-year. first during We procedure quarter growing to Shifting XX% the saw
slowdown of As result I volumes in did indicated in earlier, March. a procedure see we a COVID-XX as
surgeons growth programs period During up the volumes procedure same the multi-specialty in year, the driven total new in largely U.S. European growth two in were online beginning coming Asia. surgery, regions sites additional and the of with months all versus first XX% XXXX, in steady
to we impact in Europe, extended quickly to started base. into our March, which shutdowns early we then installed U.S. As of moved the see
year-over-year procedure As to volume XX%. a slowed growth March, during result,
able within systems QX of growth relatively recent was performance our One were procedure strong the Asia. the in we installed reasons maintain in to volume
procedure to regions, first procedures the had April. done the have with within hospitals. of partially pandemic seen slow in This rapid those acceleration the volumes but was more even into the to growth and those being Taiwan, significant Japan do in due Specifically in during quarter onset and we of
increased system volumes favorable a Taiwanese hospital surgery. saw general the steady rapid leveraging Japan. installed urology, program as Senhance in Japanese across of of saw The the The start to sites gynecology, that in the result at newly Senhance is reimbursement Kitakyushu, a surgery volume general applicable busy and
of that XX year. Senhance system One the at the of was sites are of the our three the first year volumes to using goals quarters the foundational number expand sites during high for to
down during the expect in the expansion and sites of slowed foundational the with has sites have to made procedures months, the elective in of progress slowdown add continue recent happy we balance foundational to these we the the are year While during year.
Turning validation. clinical to
focus on data systems. robotic surgical clinical traditional primarily to the of around on continue laparoscopy relative to cost as Senhance development impact the evidence. other XXXX, Moving to of we health well In economic as
data we instruments millimeter addition, to on and will X continue the of incisions. In use of benefit develop the smaller
and clearance FDA Intelligence Vision received the we or quarter, first surgery and robotic in the First required in in installed a camera In reduce ISU. base in represents advance tasks with efforts. movement Machine with the for Surgical with system the existing movements, the link is expansion the the portfolio recognize meaningful software augmented instrument a system Unit Senhance hardware cognitive instruments, intelligence ability to system Moving System decide to and to visualization. of compatible This
ISU for our up generation approval ISU, continue to incremental intelligence Machine QX next features, namely additional FDA in to of the Following we submit we FDA. now the and augmented capabilities which plan on to Vision pursue
the third expansion system, indication, initial with to the of with Senhance which devoted the for our we on focused surgery to the also XXXX. efforts use FDA indications now of general the file quarter expect a during with We’re
of timelines on regulatory As these noted U.S. the process the as impact a COVID-XX earlier, shifted result of in the have
the capital on Finally, funding side.
that and capital we have response need I before both a meet have we earlier, COVID our of taken number goals. ensure As to to to the to continue in steps we noted XXXX
Turning to year full guidance.
the exists that the within specific currently operating of results. uncertainty financial outbreak extent the healthcare and global we of on or market, our COVID-XX the Given predict duration cannot the impact
of a result, revenue As year $X withdrawing to full announced we’re million million. previously XXXX our guidance $X.X
times. unprecedented the very exists our response recap, during proud and uncertain Senhance and opportunity that for I'm of remain team we about very these To excited and their
near We sheet, strong the drive strategy of on increase term long-term COVID-XX, the of drive installed the we our believe capabilities and diligently clinical Senhance. bolster execute well our Despite Senhance. balance positioned to base, growth to of by to momentum we have worked are systems caused the adoption worldwide, our continue disruptions data in our to continue of and utilization develop the expand
line the open to like now would I that, With questions. for
